|本期目录/Table of Contents|

[1]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387-392.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(04):387-392.[doi:10.3969/j.issn.1672-271X.2021.04.011]
点击复制

HR+/HER2-乳腺癌内分泌治疗的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年04期
页码:
387-392
栏目:
综述
出版日期:
2021-08-10

文章信息/Info

Title:
The trend of endocrine therapeutic approach in HR+/HER2-breast cancer
作者:
地里呼玛尔·吐鲁洪; 李欣芳; 王少华
作者单位：210002南京，南京大学医学院附属金陵医院（东部战区总医院）全军普通外科研究所[地里呼玛尔·吐鲁洪（医学博士研究生）、李欣芳、王少华]
Author(s):
Dilihumaer Tuluhong;  LI Xin-fang ;  WANG Shao-hua
（Research Institute of General Surgery，Jinling Hospital，Nanjing University School of Medicine/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China）
关键词:
乳腺癌; 内分泌治疗; 靶向治疗; 内分泌联合靶向治疗; 预后
Keywords:
breast cancer;  endocrine therapy;  targeted therapy;  drug combination;  prognosis
分类号:
R736
DOI:
10.3969/j.issn.1672-271X.2021.04.011
文献标志码:
A
摘要:
乳腺癌在当今社会女性癌症类型中具有高发生率及高死亡率特征。根据激素受体（HR）和人表皮因子生长受体-2（HER2）表达的不同，在分子分型上将乳腺癌分为五型。其中占比约70%的HR+/HER2-（包含Luminal A型、Luminal B HER2-型）类型，为乳腺癌治疗的重中之重。除手术及非手术放化疗等传统疗法外，内分泌治疗在这一类型患者的治疗方案中有着举足轻重的地位。20世纪以来，多种内分泌治疗方法应运而生，为无数患者带来了曙光。文章从雌激素受体拮抗剂、芳香化酶抑制剂以及内分泌联合靶向等方面对激素受体阳性的乳腺癌患者内分泌治疗的发展历史以及最新的临床研究结果进行综述。
Abstract:
Breast cancer (BC) is one of the top types of the malignant tumors in today’s society, characterized by high morbidity and mortality. In terms of molecular typing, breast cancer is categorized into five subtypes according to the expression level of hormone receptor (HR) and human epidermal growth factor receptor type2 (HER2). Patients with HR+/HER2- (includingLuminal A type, Luminal B HER2- type) breast cancer subtype account for nearly 70% of the total cases. Except conventional therapies, including surgery and non-surgical chemoradiotherapy, endocrine therapeutic strategy is pivotally emphasized. A series of endocrine therapy pharmaceutical studies have been emerged consecutively since the beginning of 20th century, and bring dawn to millions of patients to live longer and more healthily. Here, we aimed to review the progress of endocrine therapy in hormone receptor-positive breast cancer patients and the latest clinical research results from the aspects of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AI), and endocrine therapy combined with targeted therapy.

参考文献/References:

[1]Siegel RL, Miller KD, Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[2]FRFPSG. Sir George Thomas Beatson,K.C.B, K.B.E[J]. Br Med J, 1933, 1(3764): 344-345.
[3]Charles BH. Classics in oncology[J]. CA Cancer J Clin, 1972, 22(4): 230-231.
[4]Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study[J]. J Clin Oncol, 1998, 16(3): 994-999.
[5]Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation[J]. Lancet, 1983, 1(8319): 257-261.
[6]Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial[J]. Lancet, 2009, 374(9707): 2055-2063.
[7]Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[8]Smith I, Yardley D, Burris H, et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial[J]. J Clin Oncol, 2017, 35(10): 1041-1048.
[9]Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial[J]. J Clin Oncol, 2013, 31(11): 1398-1404.
[10]De Placido S, Gallo C, De Laurentiis M, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(4): 474-485.
[11]Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer[J]. Lancet, 2005, 365(9453): 60-62.
[12]Breast International Group 1-98 Collaborative G, Thurlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J]. N Engl J Med, 2005, 353(26): 2747-2757.
[13]Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years[J]. N Engl J Med, 2016, 375(3): 209-219.
[14]Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer[J]. N Engl J Med, 2018, 379(2): 122-137.
[15]Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2015, 372(5): 436-446.
[16]Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997-3005.
[17]Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial[J]. Lancet Oncol, 2015, 16(1): 67-75.
[18]Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
[19]Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial[J]. Lancet Oncol, 2010, 11(12): 1135-1141.
[20]Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial[J]. J Natl Cancer Inst, 2014, 106(1): djt337.
[21]Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial[J]. J Clin Oncol, 2004, 22(9): 1605-1613.
[22]Rugo HS, Andre F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer[J]. Ann Oncol, 2020, 31(8): 1001-1010.
[23]Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2020, 21(3): 345-357.
[24]Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol, 2012, 30(22): 2718-2724.
[25]Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[26]Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(7): 904-916.
[27]Andre F, O’regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol, 2014, 15(6): 580-591.
[28]陈涛, 王璇, 程凯, 等. CD47在乳腺癌及癌旁组织中的表达及其意义[J]. 东南国防医药, 2018, 20(5): 501-505.
[29]Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
[30]Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915.
[31]Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24): 2465-2472.
[32]Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
[33]Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial[J]. JAMA Oncol, 2020，6(1):116-124.
[34]Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer[J]. N Engl J Med, 2016, 375(18): 1738-1748.
[35]Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425-439.
[36]Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor[J]. J Clin Oncol, 2013, 31(17): 2128-2135.
[37]Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(6): 806-815.

相似文献/References:

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
[2]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[3]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[4]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[5]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[6]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(04):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
[7]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(04):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
[8]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
[9]吴勤研,蓝晓红,吴波,等.基于生物信息技术分析人参皂苷防治乳腺癌的作用机制[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
　WU Qin-yan,LAN Xiao-hong,WU Bo,et al.Analysis of the mechanism of action of ginsenosides in preventing and treating breast cancer based on bioinformatics technology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
[10]林慧,陈佳菁,郭志锋,等.miR-9-5p在乳腺癌组织中的表达与生物信息学分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]
　LIN Hui,CHEN Jiajing,GUO Zhifeng,et al.Expression and bioinformatic analysis of miR-9-5p in breast cancer tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(04):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]

备注/Memo

备注/Memo:
基金项目：国家临床重点专科军队建设项目(2014ZDZK002)
更新日期/Last Update: 2021-08-10